2 200

Cited 24 times in

Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type

DC FieldValueLanguage
dc.contributor.author금웅섭-
dc.contributor.author김귀언-
dc.contributor.author김용배-
dc.contributor.author김주항-
dc.contributor.author서창옥-
dc.contributor.author심수정-
dc.contributor.author양우익-
dc.contributor.author조재호-
dc.date.accessioned2014-12-21T16:42:10Z-
dc.date.available2014-12-21T16:42:10Z-
dc.date.issued2007-
dc.identifier.issn0360-3016-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/96189-
dc.description.abstractPURPOSE: To determine whether there are any differences in therapeutic response, patterns of systemic recurrence, and prognosis of patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type, by the cyclooxygenase-2 (COX-2) expression. PATIENTS AND METHODS: Thirty-four patients with Ann Arbor Stage I and II extranodal NK/T-cell lymphoma who underwent chemotherapy or radiotherapy, or both, were retrospectively reviewed. These patients were divided into two groups according to their immunohistochemical staining for COX-2 expressions: a COX-2-negative group (n = 10 patients) and a COX-2-positive group (n = 24 patients). The treatment response, patterns of treatment failure, and survival data for the patients were compared between the COX-2-positive and negative groups. RESULTS: There was no significant difference in the clinical profiles between the COX-2-negative and COX-2-positive groups. All patients (100%) in the COX-2-negative group achieved complete response after initial treatment, whereas only 14 patients (58%) in the COX-2-positive group achieved complete response (p = 0.03). Compared with the patients in the COX-2-negative group, those in the COX-2-positive group had a significantly lower 2-year systemic recurrence-free survival rate (100% for the COX-2-negative group vs. 54% for the COX-2-positive group) (p = 0.02) and a decreased 5-year overall survival rate (70% for the COX-2-negative group vs. 32% for the COX-2-positive group) (p = 0.06). CONCLUSION: Cyclooxygenase-2 expression can serve as a predictive factor for poor treatment response, higher systemic recurrence, and unfavorable prognosis in patients with extranodal NK/T-cell lymphoma, nasal type.-
dc.description.statementOfResponsibilityopen-
dc.format.extent31~38-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHCyclooxygenase 2/metabolism*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHead and Neck Neoplasms/drug therapy-
dc.subject.MESHHead and Neck Neoplasms/metabolism*-
dc.subject.MESHHead and Neck Neoplasms/mortality-
dc.subject.MESHHead and Neck Neoplasms/radiotherapy-
dc.subject.MESHHumans-
dc.subject.MESHLymphoma, T-Cell/drug therapy-
dc.subject.MESHLymphoma, T-Cell/metabolism*-
dc.subject.MESHLymphoma, T-Cell/mortality-
dc.subject.MESHLymphoma, T-Cell/radiotherapy-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Proteins/metabolism*-
dc.subject.MESHNose Neoplasms/drug therapy-
dc.subject.MESHNose Neoplasms/metabolism-
dc.subject.MESHNose Neoplasms/radiotherapy-
dc.subject.MESHPrognosis-
dc.subject.MESHRecurrence-
dc.subject.MESHRemission Induction-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTreatment Outcome-
dc.titleClinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSu Jung Shim-
dc.contributor.googleauthorWoo-Ick Yang-
dc.contributor.googleauthorGwi Eon Kim-
dc.contributor.googleauthorJoo Hang Kim-
dc.contributor.googleauthorChang Ok Suh-
dc.contributor.googleauthorJae Ho Cho-
dc.contributor.googleauthorYong Bae Kim-
dc.contributor.googleauthorWoong Sub Koom-
dc.contributor.googleauthorEunah Shin-
dc.identifier.doi10.1016/j.ijrobp.2006.07.1387-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00273-
dc.contributor.localIdA00321-
dc.contributor.localIdA00945-
dc.contributor.localIdA01919-
dc.contributor.localIdA02195-
dc.contributor.localIdA02300-
dc.contributor.localIdA03901-
dc.contributor.localIdA00744-
dc.relation.journalcodeJ01157-
dc.identifier.eissn1879-355X-
dc.identifier.pmid17049184-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0360301606027763-
dc.subject.keywordNatural Killer/T-cell lymphoma-
dc.subject.keywordCOX-2-
dc.subject.keywordSystemic recurrence-
dc.contributor.alternativeNameKoom, Woong Sub-
dc.contributor.alternativeNameKim, Gwi Eon-
dc.contributor.alternativeNameKim, Yong Bae-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameSuh, Chang Ok-
dc.contributor.alternativeNameShim, Su Jung-
dc.contributor.alternativeNameYang, Woo Ick-
dc.contributor.alternativeNameCho, Jae Ho-
dc.contributor.affiliatedAuthorKoom, Woong Sub-
dc.contributor.affiliatedAuthorKim, Gwi Eon-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorSuh, Chang Ok-
dc.contributor.affiliatedAuthorShim, Su Jung-
dc.contributor.affiliatedAuthorYang, Woo Ick-
dc.contributor.affiliatedAuthorCho, Jae Ho-
dc.contributor.affiliatedAuthorKim, Yong Bae-
dc.rights.accessRightsnot free-
dc.citation.volume67-
dc.citation.number1-
dc.citation.startPage31-
dc.citation.endPage38-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.67(1) : 31-38, 2007-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.